MTI Secures $3.2M USD Financing Round
Metabolomic Technologies Inc. (MTI) announced the successful completion of a $3.2M USD Series A raise. The company's lead product, PolypDx™, is the world's first and only urine test for colorectal cancer screening. Developed in Canada, and patented globally, PolypDx™ is currently being assessed by the Alberta provincial health system in Canada as a way to increase overall screening efforts to help manage the disease of colorectal cancer. The next critical step to bring MTI's innovative test to patients, is a multi-centre pivotal trial in the US. Evidence generated from the trial will provide the basis for a commercial launch, clinical acceptance and remimbursement of PolypDx™.